3515

Traish AM, Mulgaonkar A, Giordano N. The dark side of 5a-reductase inhibitors’ therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. Korean J Urol. 2014;55(6):367–79. https://pubmed.ncbi.nlm.nih.gov/24955220/

3516

Cindolo L, Pirozzi L, Fanizza C, et al. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol. 2015;68(3):418–25. https://pubmed.ncbi.nlm.nih.gov/25465970/

3517

Roehrborn CG, Bruskewitz R, Nickel JC, et al. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol. 2004;171(3):1194–8. https://pubmed.ncbi.nlm.nih.gov/14767299/

3518

Irwig MS. How routine pharmacovigilance failed to identify finasteride’s persistent sexual side effects. Andrology. 2022;10(2):207–8. https://pubmed.ncbi.nlm.nih.gov/34713622/

3519

Zhang AY, Xu X. Prevalence, burden, and treatment of lower urinary tract symptoms in men aged 50 and older: a systematic review of the literature. SAGE Open Nurs. 2018;4:2377960818811773. https://pubmed.ncbi.nlm.nih.gov/33415211/

3520

Metcalfe C, Poon KS. Long-term results of surgical techniques and procedures in men with benign prostatic hyperplasia. Curr Urol Rep. 2011;12(4):265–73. https://pubmed.ncbi.nlm.nih.gov/21484456/

3521

Burnett AL, Wein AJ. Benign prostatic hyperplasia in primary care: what you need to know. J Urol. 2006;175(3 Pt 2):S19–24. https://pubmed.ncbi.nlm.nih.gov/16458735/

3522

Burnett AL, Wein AJ. Benign prostatic hyperplasia in primary care: what you need to know. J Urol. 2006;175(3 Pt 2):S19–24. https://pubmed.ncbi.nlm.nih.gov/16458735/

3523

Gu F. Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China. Chin Med J. 2000;113(4):299–302. https://pubmed.ncbi.nlm.nih.gov/11775222/

3524

Kraft TS, Stieglitz J, Trumble BC, Martin M, Kaplan H, Gurven M. Nutrition transition in 2 lowland Bolivian subsistence populations. Am J Clin Nutr. 2018;108(6):1183–95. https://pubmed.ncbi.nlm.nih.gov/30383188/

3525

Trumble BC, Stieglitz J, Rodriguez DE, Linares EC, Kaplan HS, Gurven MD. Challenging the inevitability of prostate enlargement: low levels of benign prostatic hyperplasia among Tsimane forager-horticulturalists. J Gerontol A Biol Sci Med Sci. 2015;70(10):1262–8. https://pubmed.ncbi.nlm.nih.gov/25922348/

3526

Cicero AFG, Allkanjari O, Busetto GM, et al. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. Arch Ital Urol Androl. 2019;91(3). https://pubmed.ncbi.nlm.nih.gov/31577095/

3527

Koskimäki J, Hakama M, Huhtala H, Tammela TL. Association of dietary elements and lower urinary tract symptoms. Scand J Urol Nephrol. 2000;34(1):46–50. https://pubmed.ncbi.nlm.nih.gov/10757270/

3528

Bravi F, Bosetti C, Dal Maso L, et al. Food groups and risk of benign prostatic hyperplasia. Urology. 2006;67(1):73–9. https://pubmed.ncbi.nlm.nih.gov/16413336/

3529

Galeone C, Pelucchi C, Talamini R, et al. Onion and garlic intake and the odds of benign prostatic hyperplasia. Urology. 2007;70(4):672–6. https://pubmed.ncbi.nlm.nih.gov/17991535/

3530

Bravi F, Bosetti C, Dal Maso L, et al. Food groups and risk of benign prostatic hyperplasia. Urology. 2006;67(1):73–9. https://pubmed.ncbi.nlm.nih.gov/16413336/

3531

Bhagwat S, Haytowitz DB, Holden JM. USDA database for the isoflavone content of selected foods: release 2.0. Agricultural Research Service, United States Department of Agriculture. https://www.ars.usda.gov/arsuserfiles/80400525/data/isoflav/isoflav_r2.pdf. Published September 2008. Accessed April 15, 2022.; https://www.ars.usda.gov/arsuserfiles/80400525/data/isoflav/isoflav_r2.pdf

3532

Wong SYS, Lau WWY, Leung PC, Leung JCS, Woo J. The association between isoflavone and lower urinary tract symptoms in elderly men. Br J Nutr. 2007;98(6):1237–42. https://pubmed.ncbi.nlm.nih.gov/17640419/

3533

Zhou Z, Wang Z, Chen C, et al. Transurethral prostate vaporization using an oval electrode in 82 cases of benign prostatic hyperplasia. Chin Med J. 1998;111(1):52–5. https://pubmed.ncbi.nlm.nih.gov/10322654/

3534

Ornish D, Weidner G, Fair WR, et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol. 2005;174(3):1065–9. https://pubmed.ncbi.nlm.nih.gov/16094059/

3535

Barnard RJ, Gonzalez JH, Liva ME, Ngo TH. Effects of a low-fat, high-fiber diet and exercise program on breast cancer risk factors in vivo and tumor cell growth and apoptosis in vitro. Nutr Cancer. 2006;55(1):28–34. https://pubmed.ncbi.nlm.nih.gov/16965238/

3536

Barnard RJ, Kobayashi N, Aronson WJ. Effect of diet and exercise intervention on the growth of prostate epithelial cells. Prostate Cancer Prostatic Dis. 2008;11(4):362–6. https://pubmed.ncbi.nlm.nih.gov/18283296/

3537

Карликовая пальма, произрастающая на восточном побережье Северной Америки. – Примеч. ред.

3538

Keehn A, Taylor J, Lowe FC. Phytotherapy for benign prostatic hyperplasia. Curr Urol Rep. 2016;17(7):53. https://pubmed.ncbi.nlm.nih.gov/27180172/

3539

Trivisonno LF, Sgarbossa N, Alvez GA, et al. Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement: a systematic review and meta-analysis. Investig Clin Urol. 2021;62(5):520–34. https://pubmed.ncbi.nlm.nih.gov/34488251/

3540

Zendehdel A, Ansari M, Khatami F, Mansoursamaei S, Dialameh H. The effect of vitamin D supplementation on the progression of benign prostatic hyperplasia: a randomized controlled trial. Clin Nutr. 2021;40(5):3325–31. https://pubmed.ncbi.nlm.nih.gov/33213976/

3541

Safwat AS, Hasanain A, Shahat A, et al. Cholecalciferol for the prophylaxis against recurrent urinary tract infection among patients with benign prostatic hyperplasia: a randomized, comparative study. World J Urol. 2019;37(7):1347–52. https://pubmed.ncbi.nlm.nih.gov/30361957/

3542

Zhang W, Wang X, Liu Y, et al. Effects of dietary flaxseed lignan extract on symptoms of benign prostatic hyperplasia. J Med Food. 2008;11(2):207–14. https://pubmed.ncbi.nlm.nih.gov/18358071/

3543

Vahlensieck W, Theurer C, Pfitzer E, Patz B, Banik N, Engelmann U. Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, randomized, placebo-controlled GRANU study. Urol Int. 2015;94(3):286–95. https://pubmed.ncbi.nlm.nih.gov/25196580/

3544

Assessment report on Cucurbita pepo L., semen. European Medicines Agency. https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-cucurbita-pepo-l-semen_en.pdf. Published September 13, 2011. Accessed August 22, 2022.; https://www.ema.europa.eu/en/medicines/herbal/cucurbitae-semen

3545

Matsuo T, Miyata Y, Sakai H. Effect of salt intake reduction on nocturia in patients with